ARVINAS, INC. Number of Reportable Segments
ARVINAS, INC. (ARVN) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-04
- ARVINAS, INC. number of reportable segments for fiscal 2024 was 1.00 Segment.
Segment
| Period end | Number of Reportable Segments 12 month |
|---|---|
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-02-11 |
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-24 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |